Investors & Media

Corporate Profile

ARS Pharmaceuticals is dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis. The Company is developing neffy™ (ARS-1), an intranasal epinephrine product in clinical development for patients and their caregivers with Type 1 allergic reactions; including food, medications and insect bites that could lead to life-threatening anaphylaxis. 

Media Relations:
Caroline Cunningham
Caroline.Cunningham@porternovelli.com

Investor Contact:
Justin Chakma
justinc@ars-pharma.com